Mizuho analyst Bradley Bowers raised the firm’s price target on Guardant Health (GH) to $100 from $75 and keeps an Outperform rating on the shares. The company reported a “broad-based” Q3 sales beat. The strong Q3 performance puts Guardant on an early trajectory towards achieving its 2028 targets, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $85 from $70 at Barclays
- Guardant Health price target raised to $100 from $75 at Canaccord
- Guardant Health Reports Strong Q3 2025 Growth
- Guardant Health: Strong Performance and Growth Potential Drive Buy Rating
- Closing Bell Movers: Meta sinks, Alphabet jumps after earnings